drugset
drugset / Trial / NCT04894305

A Study of Ad26.COV2.S in Healthy Adults (COVID-19)

NCT04894305 ↗

Phase 1 Completed 380 enrolled Janssen Vaccines & Prevention B.V.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S (0.3 milliliter \[mL\] versus 0.5 mL) and to demonstrate non-inferiority (NI) of Ad26.COV2.S (0.3 mL versus 0.5 mL), 28 days after vaccination.

Timeline

Start
2021-05-25
Primary completion
2021-12-08
Completion
2021-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad26.COV2.S Vaccine 0.3 ml Intramuscular
Subject Ad26.COV2.S Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.